potassium [R-(Z)]-12-hydroxy-9-octadecenoate | 7492-30-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: potassium [R-(Z)]-12-hydroxy-9-octadecenoate
• 英文别名: potassium R-(Z)-12-hydroxy-9-octadecenoate；ricinoleic acid, potassium salt；ricinoleic acid potassium salt；MEN 11938；(R)-ricinolic acid ; potassium-salt；(R)-Ricinolsaeure; Kalium-Salz；Potassium ricinoleate；potassium;(Z,12R)-12-hydroxyoctadec-9-enoate
• CAS: 7492-30-0
• 化学式: C₁₈H₃₃O₃*K
• 分子量: 336.557
• InChiKey: VAKMIIPDYZXBEV-DPMBMXLASA-M

物化性质

• LogP：
  5.701 (est)
• 物理描述：
  Liquid
• 颜色/状态：
  White paste
• 溶解度：
  Soluble in water

计算性质

• 辛醇/水分配系数(LogP)：
  0.75
• 重原子数：
  22
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  3

ADMET

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒物A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

迹象和症状据说可以通过刺激小肠粘膜上的局部作用产生运动活动......催泄....../蓖麻酸/

/SIGNS AND SYMPTOMS/ SAID TO PRODUCE.../CATHARSIS/...BY STIMULATING MOTOR ACTIVITY THROUGH A LOCAL ACTION ON THE SMALL INTESTINAL MUCOSA. /RICINOLEIC ACID/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

/其他毒性信息/ 以10%乙醇、10% Tween 80和80%盐水为溶剂的蓖麻油中的蓖麻酸（ricinoleic acid）的抗痛觉活性进行了研究，研究对象为5只体重250至350克的雄性白化Dunkin-Hartley豚鼠和8至10只体重20至25克的雄性瑞士小鼠。进行了一系列实验。在第一次实验中，将蓖麻酸（900微克/只小鼠）单次涂抹在每只小鼠右爪腹侧表面。涂抹测试物质30分钟后，通过足底注射角叉菜胶（以诱导水肿）。与仅使用溶剂相比，蓖麻酸显著延长了对热刺激的反应时间。当先连续8天涂抹蓖麻酸（900微克/只小鼠）再进行角叉菜胶的足底注射时，同样观察到与仅使用溶剂的对照组相比，对热刺激的爪退缩潜伏期明显延长。另一项实验涉及连续8天局部涂抹蓖麻酸（900微克/只小鼠）或连续4天在右爪腹侧表面进行钾蓖麻酸盐（30微克/只小鼠）的皮内注射。在后肢爪上第一天注射了弗氏佐剂。局部涂抹后对疼痛刺激（热）的爪退缩潜伏期至少在2周内增加。皮内注射钾蓖麻酸盐诱导了显著的抗痛觉效果，持续时间至少为3周。

/OTHER TOXICITY INFORMATION/ The antinociceptive activity of ricinoleic acid (in peanut oil), dissolved in a vehicle containing 10% ethanol, 10% Tween 80, and 80% saline, /was examined/ using groups of 5 male albino Dunkin-Hartley guinea pigs (weights = 250 to 350 g) and groups of 8 to 10 male Swiss mice (weights =20 to 25 g). A series of experiments was performed. In the first experiment, a single topical application of Ricinoleic Acid (900 ug/mouse) was made to the ventral surface of the right paw of each mouse. Test substance application was followed by intraplantar injection with carrageenan (to induce edema) 30 min later. Ricinoleic acid significantly reduced the reaction time to a heat stimulus, compared to treatment with the vehicle. When intraplantar injection with carageenan was preceded by repeated (8 days) topical applications of ricinoleic acid (900 ug/mouse), again, a marked prolongation of paw withdrawal latency to heat, compared to the vehicle control group, was noted. Another experiment involved the repeated local application (8 days) of ricinoleic acid (900 ug/mouse) or the repeated (4 days) intradermal injection of potassium ricinoleate (30 ug/mouse) on the ventral surface of the right paw. Freund's adjuvant had been injected into the hindpaw on the first day. The paw withdrawal latency to a painful stimulus (heat) after topical application was increased over at least 2 weeks. The intradermal injection of potassium ricinoleate induced a significant antinociceptive effect that lasted for at least 3 weeks.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  potassium [R-(Z)]-12-hydroxy-9-octadecenoate 、 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 120.0~130.0 ℃ 、9.81 MPa 条件下， 生成 癸二酸 、 仲辛酮
  参考文献：
  名称：

  Treibs; Rothe, Chemische Berichte, 1951, vol. 84, p. 370,375

  摘要：

  DOI：

文献信息

• SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES
  申请人：Ohio State Innovation Foundation

  公开号：US20140155577A1

  公开（公告）日：2014-06-05

  Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nanotubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

  揭示了与受保护或未受保护的氨基酸或肽连接的疏水药物的共轭物。所述的共轭物是两性的，可以自组装成纳米管。还描述了包含这些共轭物的纳米管，可以具有高药物载荷并保护药物免受降解或排泄。这些纳米管非常适合向个体输送疏水和不稳定的药物。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• [EN] BENZOXAZOLE AND BENZODIAZOLE UV-A SUNSCREENS<br/>[FR] ECRANS SOLAIRES A BASE DE BENZOXAZOLE ET DE BENZODIAZOLE
  申请人：DSM IP ASSETS BV

  公开号：WO2004000256A1

  公开（公告）日：2003-12-31

  The present invention relates to 1,3- benzoxazole or benzodiazole UV-A sunscreens and to compositions, in particular topical compositions, containing the above UV-A sunscreens.

  本发明涉及1,3-苯并噁唑或苯并二唑紫外线A防晒剂，以及含有上述紫外线A防晒剂的组合物，特别是含有上述紫外线A防晒剂的局部组合物。
• NITROGEN-CONTAINING COMPOUNDS SUITABLE FOR USE IN THE PRODUCTION OF POLYURETHANES
  申请人：Evonik Degussa GmbH

  公开号：US20180194889A1

  公开（公告）日：2018-07-12

  The present invention provides for the use of nitrogen compounds of formula (I) and/or of corresponding quaternized and/or protonated compounds for production of polyurethanes, compositions containing these compounds and polyurethane systems, especially polyurethane foams, which have been obtained using the compounds.

  本发明提供了使用式(I)的氮化合物和/或相应的季铵化和/或质子化化合物用于生产聚氨酯、含有这些化合物的组合物和聚氨酯体系的方法，特别是使用这些化合物获得的聚氨酯泡沫。
• [EN] MICROCAPSULES WITH UV FILTER ACTIVITY AND PROCESS FOR PRODUCING THEM<br/>[FR] MICROCAPSULES POSSEDANT UNE ACTIVITE DE FILTRE UV ET PROCEDE DE FABRICATION DE CELLES-CI
  申请人：DSM IP ASSETS BV

  公开号：WO2005053631A1

  公开（公告）日：2005-06-16

  The invention provides a process for producing microcapsules with UV filter activity, wherein at least one type of crosslinkable chromophore with UV-A and/or UV-B and/or UV-C filter activity and optionally at least one type of crosslinkable monomer which does not have UV-A and/or UV-B and/or UV-C filter activity are subjected to a crosslinking reaction in the absence of non-crosslinkable chromophores with UV-A and/or UV-B and/or UV-C filter activity and microcapsules obtainable by this process.

  该发明提供了一种生产具有紫外线过滤活性的微胶囊的方法，其中至少一种具有紫外线A和/或紫外线B和/或紫外线C过滤活性的可交联色素和可选地至少一种不具有紫外线A和/或紫外线B和/或紫外线C过滤活性的可交联单体在不存在不具有紫外线A和/或紫外线B和/或紫外线C过滤活性的不可交联色素的情况下进行交联反应，并通过该方法获得的微胶囊。